The interaction between AHNAK2 and TGFB1 could potentially contribute to the establishment of an immunosuppressive microenvironment, facilitating tumor progression and highlighting AHNAK2 as a potential target for cancer-related research and therapeutic interventions. The gene discussed is TGFB1; the disease is cancer.